Significant research to evaluate treatments for cancer is underway at Renown including studies relevant to breast, gynecological, colorectal, and prostate cancer. Here are some highlights:
Anal and Colorectal Cancer
Radiation therapy is a cornerstone in the management of anal canal and rectal cancer. Acute radiation enteritis (diarrhea), the most common characteristic of acute radiation effects in pelvic radiotherapy, is an uncomfortable side effect. The addition of chemotherapy may exacerbate the severity, sometimes resulting in interruption of treatment.
RTOG 0315 is a clinical trial designed and developed by the Radiation Therapy Oncology Group (RTOG) of the American College of Radiology (ACR). This is a Randomized, Double Blind, Placebo Controlled Phase III Study to Determine the Efficacy of Sandostatin LAR Depot (octereotide acetate) in Preventing or Reducing the Severity of Chemoradiation-Induced Diarrhea in Patients With Anal or Rectal Cancer. The drug Sandostatin LAR is provided at no cost to participants enrolled in the study.
Dr. Lim is the Principal Investigator affiliated with the Gynecologic Oncology Group, also referred to as GOG. GOG is one of the National Cancer Institute's (NCI) sponsored research groups. GOG's focus of research is women with pelvic malignancies. Approximately 45 individual clinical trials are active at any one time within GOG for patients with a variety of gynecologic malignancies, including cancers that arise from the ovaries, uterus, cervix, vagina and vulva. Currently there are Phase III clinical trials available for ovarian, uterine and cervical cancer for patients interested in participating in these studies through the Center of Hope at Renown.
In addition, Center of Hope at Renown has been chosen by Eli Lilly as a clinical trial site for a Phase III study offering primary treatment for women diagnosed with advanced ovarian cancer. Eli Lilly is a leading pharmaceutical company involved in the development of new chemotherapy drugs made possible through research.
Peter Lim, M.D.
A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5FU), Leucovorin, and Oxaliplatin (mFOLFOX6) every Two Weeks With Bevacizumab to the Same Regimen Without Bevacizumab for the Treatment of Patients With Resected Stages II and III Carcinoma of the Colon.
Colorectal cancer is the third most common cause of death from malignancy in both men and women in the United States. Although surgery remains the mainstay of treatment for state II and III colon cancer, a substantial minority of patients are not cured by surgery alone. Studies from the NSABP and other cooperative groups have clearly demonstrated that adjuvant chemotherapy has altered the natural history of patients with colon cancer.
This study will evaluate whether the addition of the anti-VEGF antibody (bevacizumab) to infusional 5-FU, leucovorin, and oxaliplatin (mFOLFOX6) will be more beneficial than mFOLFOX6 alone in prolonging disease free survival (DFS) and survival (S) in patients with resected stage II and III carcinoma of the colon while evaluating adverse events possibly related to bevacizumab.
Steven A. Schiff, M.D